For diseases where tocilizumab has been effective (rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, and cytokine release syndrome), systemic inflammation is a feature of the disease and IL-6 levels are elevated. Here, IL6 is linked to systemic-onset juvenile idiopathic arthritis.